Extracellular DNA as a Prognostic and Therapeutic Target in Mouse Colitis under DNase I Treatment

Area of Science:

• Gastroenterology
• Immunology
• Molecular Biology

Background:

• Inflammatory bowel disease (IBD) involves chronic inflammation of the gastrointestinal tract.
• Extracellular DNA (ecDNA) is implicated in various inflammatory conditions.
• The role of ecDNA in IBD pathogenesis and as a therapeutic target remains unclear.

Purpose of the Study:

• To investigate extracellular DNA (ecDNA) as a prognostic and/or therapeutic target in experimental inflammatory bowel disease (IBD).
• To assess the impact of DNase I administration on colitis severity and associated biomarkers.

Main Methods:

• Acute colitis was induced in C57BL/6J mice using 2% dextran sulfate sodium (DSS).
• DNase I was administered intravenously on days 3 and 7 post-DSS induction.
• Measurements included disease activity index, weight loss, stool consistency, colon parameters, myeloperoxidase activity, and TNF-α levels.

Main Results:

• DSS-induced colitis mice exhibited significant weight loss, altered stool consistency, and increased colon inflammation markers (myeloperoxidase, TNF-α).
• DNase I treatment showed a trend towards improvement in myeloperoxidase activity and TNF-α levels compared to untreated colitis groups.
• No significant differences in plasmatic ecDNA levels were observed between DNase-treated and untreated colitis groups throughout the study.

Conclusions:

• The study did not confirm a direct role for ecDNA levels as a prognostic marker in this experimental colitis model.
• DNase I administration demonstrated some beneficial effects on inflammatory markers, suggesting potential therapeutic value in IBD.
• Further research is warranted to explore the therapeutic potential of DNase I in inflammatory bowel disease.